Anemia in solid organ transplantation

Annals of Transplantation

Volumn 17, Issue 2, 2012, Pages 86-100

  Małyszko, Jolanta ^a   Watschinger, Bruno ^b   Przybyłowski, Piotr ^c   Durlik, Magdalena ^d  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Anemia; Heart transplantation; Liver transplantation; Renal transplantation

Indexed keywords

ALEMTUZUMAB; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CREATININE; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FOLIC ACID; GANCICLOVIR; HEMOGLOBIN; INTERFERON; IRON; LAMIVUDINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; RETINOIC ACID; RIBAVIRIN; SERASPENIDE; TACROLIMUS; THEOPHYLLINE; THYMOCYTE ANTIBODY; TRIMETHOPRIM; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; AGING; ANEMIA; ANTIPROLIFERATIVE ACTIVITY; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; COMORBIDITY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; FOLATE DEFICIENCY ANEMIA; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HEPATITIS C; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IRON DEFICIENCY ANEMIA; IRON THERAPY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TRANSPLANTATION; MACROCYTIC ANEMIA; MICROCYTIC ANEMIA; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT ANEMIA; PREVALENCE; QUALITY OF LIFE; REVIEW; VIRUS INFECTION;

EID: 84863539729     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/aot.883227     Document Type: Review

References (120)

1. Ojo AO, Held PJ, Port FK et al: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med, 2003; 349: 931.
2. Malyszko J, Durlik M, Przybylowski P: Kidney dysfunction after non renal solid organ transplantation. Ann Transplant, 2009; 14: 71-79.
3. Hsu CY: Epidemiology of anemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens, 2002; 11: 337-41.
4. Astor BC, Muntner P, Levin A et al: Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (19881994). Arch Intern Med, 2002; 162: 1401-8.
5. Hsu, CY, McCulloch, CE, Curhan, GC: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol, 2002; 13: 504-10.
6. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood, 2003; 102: 783-88.
7. Mix TC, Kazmi W, Khan S et al: Anemia: a continuing problem following kidney transplantation. Am J Transplant, 2003; 3: 1426-33.
8. Yorgin PD, Scandling JD, Belson A et al: Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant, 2002; 2: 429-35.
9. nd ed, Hoffman, R, Benz, EJ Jr, Shattil SJ et al., (eds.), Churchill Livingstone, New York 1995.
10. World Health Organization: Nutritional anaemias: Report of a WHO Scientific Group. World Health Organ Tech Rep Ser, 1968; 405: 5-37.
11. Locatelli F, Aljama P, Bárány P et al: European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant, 2004; 19(Suppl.2): ii1-47.
12. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis, 2006; 47: S1-S166.
13. Locatelli F, Covic A, Eckardt KU et al: ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant, 2009; 24: 348-54.
14. Lorenz M, Kletzmayr J, Perschl A et al: Anemia and iron deficiencies among long-term renal transplant recipients. J Am Soc Nephrol, 2002; 13: 794-97.
15. Winkelmayer WC, Chandraker A, Alan Brookhart M et al: A prospective study of anaemia and long-term outcomes in kidney transplant recipients. Nephrol Dial Transplant, 2006; 21: 3559-66.
16. Vanrenterghem Y, Ponticelli C, Morales et al: Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant, 2003; 3: 835-45.
17. Chadban SJ, Baines L, Polkinghorne K et al: Anemia after kidney transplantation is not completely explained by reduced kidney function. Am J Kidney Dis, 2007; 49: 301-9.
18. Jiménez Alvaro S, Marcén R, Teruel JL et al: Management of chronic kidney disease after renal transplantation: is it different from nontransplant patients? Transplant Proc, 2009; 41: 2409-11.
19. Afzali B, Al-Khoury S, Shah N et al: Anemia after renal transplantation. Am J Kidney Dis, 2006; 48: 519-36.
20. Shah N, Al-Khoury S, Afzali B et al: Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation, 2006; 81: 1112-18.
21. Winkelmayer WC, Chandraker A: Posttransplantation anemia: management and rationale. Clin J Am Soc Nephrol, 2008; 3: S49-55.
22. Unal A, Sipahioglu MH, Akcakaya M et al: An underappreciated problem in renal transplant recipients: anemia. Transplant Proc, 2008; 40: 1399-403.
23. Kolonko A, Pinocy-Mańdok J, Kocierz M et al: Anemia and erythrocytosis after kidney transplantation and 5-year graft function and survival. Transplant Proc, 2009; 41: 3046-51.
24. Jones H, Talwar M, Nogueira JM et al: Anemia After Kidney Transplantation; Its Prevalence, Risk Factors, and Independent Association With Graft and Patient Survival: A Time-Varying Analysis. Transplantation, 2012; 93: 923-28.
25. Karthikeyan V, Karpinski J, Nair RC et al: The burden of chronic kidney disease in renal transplant recipients. Am J Transplant, 2004; 4: 262-69.
26. Costa de Oliveira CM, Mota MU, Mota RS et al: Prevalence and staging of chronic kidney disease in renal transplant recipients. Clin Transplant, 2009; 23: 628-36.
27. Marcén R, del Castillo D, Capdevila L et al: Achieving chronic kidney disease treatment targets in renal transplant recipients: results from a cross-sectional study in Spain. Transplantation, 2009; 87: 1340-46.
28. Gentil MA, Pérez-Valdivia MA, González-Roncero FM et al: Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets. Transplant Proc, 2008; 40: 2916-18.
29. Malyszko J, Malyszko JS, Mysliwiec M: Anemia prevalence and a possible role of hepcidin in its pathogenesis in kidney allograft recipients. Transplant Proc, 2009; 41: 3056-59.
30. Ott U, Busch M, Steiner T, Wolf G: Anemia after renal transplantation: an underestimated problem. Transplant Proc, 2008; 40: 3481-84.
31. Kamar N, Rostaing L: Negative impact of oneyear anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation, 2008; 85: 1120-24.
32. Turkowski-Duhem A, Kamar N, Cointault O et al: Predictive factors of anemia within the first year post renal transplant. Transplantation, 2005; 80: 903-9.
33. Turkowski-Duhem A, Kamar N, Cointault O et al: Predictive factors of postrenal transplant anemia. Transplant Proc, 2005; 37: 1009-11.
34. Wilflingseder J, Kainz A, Perco P et al: Molecular predictors for anaemia after kidney transplantation. Nephrol Dial Transplant, 2009; 24: 1015-23.
35. Gill JS, Abichandani R, Khan S et al: Opportunities to improve the care of patients with kidney transplant failure. Kidney Int, 2002; 61: 2193-200.
36. Imoagene-Oyedeji AE, Rosas SE, Doyle AM et al: Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: Risk factors and implications for mortality. J Am Soc Nephrol, 2006; 17: 3240-47.
37. Al-Uzri A, Yorgin PD, Kling PJ: Anemia in children after transplantation: etiology and the effect of immunosuppressive therapy on erythropoiesis. Pediatr Transplant, 2003; 7: 253-64.
38. Winkelmayer WC, Kewalramani R, Rutstein Met al: Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol, 2004; 15: 1347-52.
39. Friend P, Russ G, Oberbauer R et al: Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function. Transplant Int, 2007; 20: 754-60.
40. Augustine JJ, Knauss TC, Schulak JA et al: Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant, 2004; 4: 2001-6.
41. Maiorano A, Stallone G, Schena A et al: Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation, 2006; 82: 908-12.
42. Thaunat O, Beaumont C, Chatenoud L et al: Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation, 2005; 80: 1212-19.
43. Goplani KR, Vanikar AV, Shah PR et al: Postrenal transplant hemolytic uremic syndrome/ thrombotic microangiopathy: Ahmedabad experience. Transplant Proc, 2008; 40: 1114-16.
44. Franco A, Hernandez D, Capdevilla L et al: De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus. Transplant Proc, 2003; 35: 1764-66.
45. Evens AM, Kwaan HC, Kaufman DB, Bennett CL: TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology. Transplantation, 2002; 74: 885-87.
46. Przybylowski P, Koc-Zorawska E, Glowinska I et al: Hemojuvelin and iron metabolism in kidney and heart allograft recipients. Transplant Proc, 2012, in press.
47. Stigant CE, Cohen J, Vivera M, Zaltzman JS: ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis, 2000; 35: 58-63.
48. Kim HC, Park SB, Han SY, Whang EA: Anemia following renal transplantation. Transplant Proc, 2003; 35: 302-3.
49. Egbuna O, Zand MS, Arbini A et al: A cluster of parvovirus B19 infections in renal transplant recipients: a prospective case series and review of the literature. Am J Transplant, 2006; 6: 225-31.
50. Moulin B, Ollier J, George F et al: Serum erythropoietin and reticulocyte maturity index after renal transplantation: a prospective longitudinal study. Nephron, 1995; 69: 259-66.
51. Besarab A, Caro J, Jerrell B et al: Dynamics of erythropoiesis following renal transplantation. Kidney Int, 1987; 32: 526-36.
52. Przybylowski P, Malyszko J, Glowinska I et al: Prevalence of iron deficiency in heart and kidney allograft recipients. Transplant Proc, 2011; 43: 3885-87.
53. Heinze G, Mitterbauer C, Regele H et al: Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Type 1 Receptor Antagonist Therapy Is Associated with Prolonged Patient and Graft Survival after Renal Transplantation. J Am Soc Nephrol, 2006; 17: 889-98.
54. Weir MR: Is anemia a predictor for mortality and loss of graft function in kidney transplant recipients? Am J Transplant, 2007; 7: 731-32.
55. Chhabra D, Grafals M, Skaro AI et al: Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol, 2008; 3: 1168-74.
56. Molnar MZ, Czira M, Ambrus C et al: Anemia is associated with mortality in kidney-transplanted patients a prospective cohort study. Am J Transplant, 2007; 7: 818-24.
57. Moore J, He X, Cockwell P et al: The impact of hemoglobin levels on patient and graft survival in renal transplant recipients. Transplantation, 2008; 86: 564-70.
58. Rigatto C, Parfrey P, Foley R et al: Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol, 2002; 13: 1084-90.
59. Rigatto C, Foley RN, Kent GM et al: Long-term changes in left ventricular hypertrophy after renal transplantation. Transplantation, 2000; 70: 570-75.
60. Djamali A, Becker YT, Simmons WD et al: Increasing hematocrit reduces early pos ttransplant cardiovascular risk in diabetic transplant recipients. Transplantation, 2003; 76: 816-20.
61. Meier-Kriesche HU, Baliga R, Kaplan B: Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation, 2003; 75: 1291-95.
62. Mudge DW, Tan KS, Miles R et al: A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation. Transplantation, 2012; 93: 822-26.
63. Akbari A, Hussain N, Karpinski J, Knoll GA: Chronic kidney disease management: comparison between renal transplant recipients and nontransplant patients with chr onic kidney dis-ease. Nephron Clin Pract, 2007; 107: c7-13.
64. Van Biesen W, Vanholder R, Veys N et al: Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation, 2005; 79: 367-68.
65. McDevitt LM, Smith LD, Somerville KT et al: A retospective assessment of pre-treatment variables on the response to darbepoetin alfa after renal transplantation. Am J Transplant, 2005; 5: 1948-56.
66. Muirhead N, Cattran DC, Zaltzman J et al: Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol, 1994; 5: 1216-22.
67. Van Loo A, Vanholder R, Bernaert P et al: Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study. Nep hrolDial Transplant, 1996; 11: 1815-21.
68. Ribes D, Kamar N, Guitard J et al: Darbepoetin-alfa in renal-transplant patients: an observational monocentric study. Clin Nephrol, 2008; 69: 102-6.
69. Sánchez-Fructuoso A, Guirado L, Ruiz JC et al: AnemiaTrans Study Group. Anemia con trol in kidney transplant patients treated with meth-oxy polyethylene glycol-epoetin beta (mi rcera):the Anemiatrans Group. Transplant Proc, 2010; 42: 2931-34.
70. Pankewycz O, Kulaylat M, Fagan L et al: A prospective protocol-based trial of darbepoetin alfa therapy to correct the early anemia following renal transplantation. Transplant Proc, 2010; 42: 3537-41.
71. Choukroun G, Kamar N, Dussol B et al: CAPRIT study Investigators. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol, 2012; 23: 360-68.
72. Felker GM, Adams KF Jr, Gattis WA et al: Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol, 2004; 44: 959-66.
73. Groenveld HF, Januzzi J, Damman K et al: Anemia and mortality in heart failure patients: a systematic review and metaanalysis. J Am Coll Cardiol, 2008; 52: 818-27.
74. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med, 2005; 352: 1011-23.
75. Malyszko J, Bachorzewska-Gajewska H, Malyszko J et al: Prevalence of chronic kidney disease (CK D) and anemia in patients with coronary ar-tery disease with normal serum creatinine, undergoing percutaneous coronary interventions (PCI), in relation to New York Heart Association (NYHA) class. IMAJ, 2010; 12: 489-93.
76. Horwich TB, Fonarow GC, Hamilton MA et al: Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol, 2002; 39: 1780-86.
77. Anand IS: Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol, 2008; 52: 501-11.
78. Androne AS, Katz SD, Lund L et al: Hemodilution is common in patients with advanced heart failure. Circulation, 2003; 107: 226-29.
79. Przybylowski P, Malyszko J, Malyszko JS: Anemia and its predictors in heart transplant recipients. Transplant Proc, 2009; 41: 3228-31.
80. Reyes CJ, Evangelista LS, Doering L et al: Physical and psychological attributes of fatigue in female heart transplant recipients. J Heart Lung Transplant, 2004; 23: 614-19.
81. Bergen GA, Sakalosky PE, Sinnott JT: Transient aplastic anemia caused by parvovirus B19 infection in a heart transplant recipient. J HeartLung Transplant, 1996; 15: 843-45.
82. Lammermeier DE, Duncan JM, Kuykendall RC et al: Cardiac transplantation in a Jehovah's witness. Tex Heart Inst J, 1988; 15: 189-91.
83. Taegtmeyer AB, Rogers P, Breen JB et al: The effects of preand post-transplant anemia on 1-y ear survival after cardiac transplantation. J Heart Lung Transplant, 2008; 27: 394-99.
84. Przybylowski P, Malyszko JS, Macdougall IC et al: Iron Metabolism, hepcidin and Anemia in Orthotopic Heart Transplantation Treated with mTOR. Transplant Proc, 2012, in press.
85. Przybylowski P, Malyszko J, Malyszko JS et al: Anemia in heart and kidney allograft recipients: is there a role for hepcidin? Transplant Proc, 2010; 42: 4255-58.
86. Zakliczyński M, Szewczyk M, Zakliczyńska H et al: Clinical application of monitoring mycophenolic acid trough concentration in heart transplant recipients single center's experience. Ann Transplant, 2005; 10: 38-45.
87. Fisher NC, Nightingale PG, Gunson BK et al: Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation, 1998; 66: 59-66.
88. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med, 1994; 331: 1110-18.
89. Gonwa TA, Mai ML, Melton LB et al: End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation, 2001; 72: 1934-39.
90. Eckardt KU: Pathophysiology of renal anemia. Clin Nephrol, 2000; 53(Suppl.): S2-S8.
91. Mach-Pascual S, Samii K, Beris P: Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. Am J Hematol, 1996; 52: 310-12.
92. Mady E, Wissa G, Khalifa A, el-Sabbagh M: Assessment of erythropoietin levels and som e iron indices in chronic renal failure and liver cirrho-sis patients. Dis Markers, 1999; 15: 229-36.
93. De Franceschi L, Fattovich G, Turrini F et al: Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology, 2000; 31: 997-1004.
94. Samuel D, Bizollon T, Feray C et al: Interferonalpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology, 2003; 124: 642-50.
95. Dumortier J, Scoazec JY, Chevallier P et al: Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol, 2004; 40: 669-74.
96. Castells L, Vargas V, Allende H et al: Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol, 2005; 43: 53-59.
97. Forman LM, Lewis JD, Berlin JA et al: The association between hepatitis C infection and survival after orthotopic liver transplantation. Gas-troenterology, 2002; 122: 889-96.
98. Shakil AO, McGurie B, Crippen J et al: A pilot study of interferon alfa and tibavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology, 2002; 36: 1253-58.
99. Ross AS, Bhan AK, Pascual M et al: Pegylated interferon alphs-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant, 2004; 18: 166-73.
100. Samuel D, Bizollan T, Feray C et al: Interferonalpha 2b plus ribavirin in patients with chronic hep atitis C after liver transplantation: a ran-domized study. Gastroenterology, 2003; 124: 642-50.
101. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M et al: Rapid suppression of hematopoiesis by standard or pegylated interferon-. Gastroenterology, 2002; 123: 141-51.
102. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002, June 10-12, 2002. Hepatology 2002; 36(Suppl.1): S3-S20.
103. Ganz T: Hepcidin a peptide hormone at the interface of innate immunity and iron metabolism. Curr Top Microbiol Immunol, 2006; 306: 183-98.
104. Trivedi HS, Trivedi M: Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C. J Clin Gastroenterol, 2005; 38: 595-98.
105. Bodenheimer HC Jr, Lindsay KL, Davis GL et al: Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology, 1997; 26: 473-77.
106. Glue P: The clinical pharmacology of ribavirin. Semin Liver Dis, 1999; 19(Suppl.1): 17-24.
107. Jarvis SM, Thorn JA, Glue P: Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosinesensitive (es)-nucleoside transporters. Br J Pharmacol, 1998; 123: 1587-92.
108. Grattagliano I, Russmann S, Palmieri VO et al: Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-induced anemia. Clin Pharmacol Ther, 2005; 78: 422-32.
109. Page T, Connor JD: The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem, 1990; 22: 379-83.
110. Saab S, Oh MK, Ibrahim AB, Durazo F et al: Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl, 2007; 13: 1032-38.
111. Hodo Y, Tsuji K, Mizukoshi E et al: Pure red cell aplasia associated with concomitant use of mycophenolate mofetil and ribavirin in posttransplant recurrent hepatitis C. Transpl Int, 2006; 19: 170-71.
112. Bardet V, Junior AP, Coste J et al: Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors. Liver Transpl, 2006; 12: 1649-54.
113. Vasilopoulos S, Hally R, Caro J et al: Erythropoietin response to post-liver transplantation anemia. Liver Transpl, 2000; 6: 349-55.
114. Kasiske BL, Vazquez MA, Harmon WE et al: Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol, 2000; 11(Suppl.15): S1-86.
115. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant, 2009; 9(Suppl.3): S1-155.
116. Ruggenenti P, Codreanu I, Cravedi P et al: Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. Clin J Am Soc Nephrol, 2006; 1: 546-54.
117. Elimelakh M, Dayton V, Park KS et al: Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica, 2007; 92: 1029-36.
118. Karaku̧ S, Kanbay M, Köseoǧlu HK et al: Causes of anemia in renal transplant recipients. Transplant Proc, 2004; 36: 164-65.
119. Nafar M, Khatami F, Kardavani B et al: Role of folic acid in atherosclerosis after kidney transplant: a double-blind, randomized, placebo-controlled clinical trial. Exp Clin Transplant, 2009; 7: 33-39.
120. Rymarz A, Durlik M, Rydzewski A: Intravenous administration of N-acetylcysteine reduces plasma total homocysteine levels in renal transplant recipients. Ann Transplant, 2009; 14: 5-9.